GSK (LON:GSK) Given New GBX 2,100 Price Target at Citigroup

GSK (LON:GSK) had its price objective dropped by equities research analysts at Citigroup from GBX 2,250 to GBX 2,100 in a report released on Wednesday,Digital Look reports. The brokerage currently has a “neutral” rating on the stock. Citigroup’s price objective would indicate a potential upside of 11.73% from the stock’s current price.

Several other analysts also recently weighed in on GSK. Berenberg Bank reiterated a “hold” rating and issued a GBX 2,000 price objective on shares of GSK in a research report on Thursday, March 26th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research report on Wednesday, January 7th. Shore Capital Group reiterated a “buy” rating on shares of GSK in a research report on Wednesday, March 25th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,500 price objective on shares of GSK in a research report on Tuesday, April 14th. Finally, UBS Group reiterated a “neutral” rating and issued a GBX 1,940 price objective on shares of GSK in a research report on Friday, January 23rd. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, GSK presently has a consensus rating of “Hold” and an average target price of GBX 2,034.29.

GSK Stock Performance

LON:GSK opened at GBX 1,879.50 on Wednesday. The business has a 50 day moving average of GBX 2,077.02 and a 200 day moving average of GBX 1,929.05. The company has a market capitalization of £75.12 billion, a price-to-earnings ratio of 13.23, a PEG ratio of 1.24 and a beta of 0.35. GSK has a 1-year low of GBX 1,288.61 and a 1-year high of GBX 2,282. The company has a debt-to-equity ratio of 106.74, a current ratio of 0.79 and a quick ratio of 0.73.

GSK (LON:GSK) last released its earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share for the quarter. The company had revenue of GBX 762.90 billion during the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%. On average, sell-side analysts predict that GSK will post 175.980975 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other GSK news, insider Anne Beal bought 196 shares of GSK stock in a transaction dated Friday, March 20th. The shares were purchased at an average cost of GBX 5,179 per share, with a total value of £10,150.84. Also, insider Jonathan Symonds bought 5,000 shares of GSK stock in a transaction dated Friday, March 20th. The shares were acquired at an average cost of GBX 1,951 per share, for a total transaction of £97,550. Insiders bought a total of 15,452 shares of company stock valued at $32,135,952 over the last three months. 0.20% of the stock is currently owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.